The Contribution of Different Formulation Components on the Aerosol Charge in Carrier-Based Dry Powder Inhaler Systems
- 258 Downloads
To measure aerosol performance of a lactose carrier/salbutamol sulphate powder blend and identify contributions of non-formulation and formulation components on the resulting aerosol charge.
A 67.5:1 (%w/w) blend of 63–90 μm lactose with salbutamol sulphate, and lactose alone (with and without the blending process), was dispersed from a Cyclohaler™ into the electrical Next Generation Impactor at 30, 60 and 90 L/min. Mass and charge profiles were measured from each dispersion, as a function of impactor stage. The charge profile from an empty capsule in the Cyclohaler™ was also studied.
Lactose deposition from the blend was significantly greater, and net charge/mass ratios were smaller, in the pre-separator compared to formulations without drug. Fine particle fraction of salbutamol sulphate increased with flow rate (9.2 ± 2.5% to 14.7 ± 2.7%), but there was no change in net charge/mass ratio. The empty capsule produced a cycle of alternating net positive and negative discharges (∼200 pC to 4 nC).
Capsule charge can ionize surrounding air and influence net charge measurements. Detachment of fine drug during aerosolisation may reduce net specific charge and lead to increased lactose deposition in the pre-separator. Increase in FPF may be due to increased force of detachment rather than electrostatic forces.
KEY WORDSCyclohaler™ electrical next generation impactor (eNGI) electrostatic lactose salbutamol sulphate
The authors would like to thank GlaxoSmithKline Australia for the provision of a postgraduate support grant, and Dr. Handoko Adi for assistance with SEM imaging.
- 24.Chapter <601>. United States Pharmacopoeia 31—National Formulary 26, United States Pharmacopoeial Convention Inc., 2008.Google Scholar
- 25.Section 2.9.18—Appendix XII C. Consistency of formulated preparations for inhalation., British Pharmacopoeia, Vol. IV, 2009.Google Scholar